Structure Therapeutics (GPCR) drew fresh attention after reporting first quarter results for the period ended March 31, 2026, with a net loss of US$75.97 million compared with US$46.83 million a year earlier.

The first quarter update and wider clinical pipeline work have come against a backdrop of a share price that is down 23.5% over the past month and 45.9% year to date, while the 1 year total shareholder return of 52.7% and 3 year total shareholder return of 36.8% point to a story where recent momentum has faded compared with earlier gains.

If this kind of earnings driven move has you comparing other opportunities in healthcare, it could be worth scanning 30 healthcare AI stocks.

With Structure Therapeutics posting a wider quarterly loss, no current revenue and a share price that has fallen sharply in recent months, investors may question whether this pullback represents a genuine buying opportunity or whether the market is already pricing in future growth.

Preferred Multiple of Price to Book: Is it justified?

With Structure Therapeutics last closing at $36.87 and trading on a P/B of 1.8x, the stock sits below both peer and wider industry reference points.

The P/B ratio compares the company’s market value to its book value, which can be a useful cross check for research stage biopharmaceutical companies that are not yet profitable and have minimal revenue. For Structure Therapeutics, valuation is being weighed against a clinical stage pipeline and balance sheet rather than current earnings.

On this measure, the stock looks cheaper than both its closest peer group and the broader US pharmaceuticals sector. The current 1.8x P/B is below the US pharmaceuticals industry average of 2.1x and well below the peer average of 5.3x. This suggests the market is assigning a lower premium to the company’s assets compared with many competitors.

Result: Price to book ratio of 1.8x (UNDERVALUED).

However, the wider clinical pipeline, ongoing net losses of US$170.34 million, and reliance on trial progress keep execution and funding risks firmly on the table.

Next Steps

If this mix of pressure and potential has you torn, it makes sense to look at the numbers yourself and decide quickly where you stand, starting with the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

Do not stop your research with a single stock. Widen your field of view and let a few focused stock lists spark fresh ideas for your portfolio.

• Target potential mispricings by scanning companies that screen as attractively valued using the 51 high quality undervalued stocks.
• Prioritise staying power by reviewing companies highlighted in the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by checking the screener containing 21 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.